Margaret A Fischl

Summary

Affiliation: University of Miami
Country: USA

Publications

  1. ncbi request reprint Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen
    Margaret A Fischl
    AIDS Clinical Research Unit R 60A, Department of Medicine, University of Miami School of Medicine, 1800 NW 10th Avenue, Miami, FL 33136, USA
    AIDS 21:325-33. 2007
  2. ncbi request reprint A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease
    Margaret A Fischl
    Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA
    J Infect Dis 188:625-34. 2003
  3. pmc Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 204:1191-201. 2011
  4. ncbi request reprint Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    JAMA 296:827-43. 2006
  5. ncbi request reprint Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial
    Margaret A Fischl
    University of Miami, School of Medicine, Department of Medicine, Florida 33136, USA
    Pharmacotherapy 23:1432-40. 2003
  6. pmc Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients
    Meenakshi Sachdeva
    Department of Microbiology and Immunology, Developmental Center for AIDS Research, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    J Acquir Immune Defic Syndr 54:447-54. 2010
  7. pmc Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes
    Liguo Niu
    Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, 1580 NW 10th Ave, Miami, FL, USA
    Vaccine 29:2110-9. 2011
  8. ncbi request reprint Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir
    Niamh Higgins
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
    Am J Addict 16:488-94. 2007
  9. ncbi request reprint Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application
    Kim Keil
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14260, USA
    Ther Drug Monit 29:103-9. 2007
  10. ncbi request reprint Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV
    Qing Ma
    University at Buffalo, Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, NY, USA
    Pharmacogenomics 8:227-35. 2007

Research Grants

Detail Information

Publications32

  1. ncbi request reprint Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen
    Margaret A Fischl
    AIDS Clinical Research Unit R 60A, Department of Medicine, University of Miami School of Medicine, 1800 NW 10th Avenue, Miami, FL 33136, USA
    AIDS 21:325-33. 2007
    ..Complex antiretroviral regimens can be associated with increased toxicity and poor adherence. Our aim was to compare the efficacy and safety of switching to two simplified, class-sparing antiretroviral regimens...
  2. ncbi request reprint A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease
    Margaret A Fischl
    Department of Medicine, University of Miami School of Medicine, Miami, Florida 33101, USA
    J Infect Dis 188:625-34. 2003
    ..A 4-drug regimen containing efavirenz plus indinavir resulted in a superior virologic response, whereas one containing nelfinavir plus indinavir resulted in an inferior response and a greater likelihood of toxicity...
  3. pmc Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results
    Paul E Sax
    Division of Infectious Diseases, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Infect Dis 204:1191-201. 2011
    ..Due to higher virologic failure with ABC/3TC in the high HIV RNA stratum, blinded treatment was stopped in this group, but study follow-up continued for all patients...
  4. ncbi request reprint Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Department of Medicine, Columbia University College of Physicians and Surgeons, New York, New York 10032, USA
    JAMA 296:827-43. 2006
    ..The International AIDS Society-USA panel has updated its recommendations as warranted by new developments in the field...
  5. ncbi request reprint Twice-daily Trizivir versus Combivir-abacavir in antiretroviral-experienced adults with human immunodeficiency virus-1 infection: a formulation-switch trial
    Margaret A Fischl
    University of Miami, School of Medicine, Department of Medicine, Florida 33136, USA
    Pharmacotherapy 23:1432-40. 2003
    ....
  6. pmc Immune exhaustion occurs concomitantly with immune activation and decrease in regulatory T cells in viremic chronically HIV-1-infected patients
    Meenakshi Sachdeva
    Department of Microbiology and Immunology, Developmental Center for AIDS Research, University of Miami Miller School of Medicine, Miami, FL 33136, USA
    J Acquir Immune Defic Syndr 54:447-54. 2010
    ..We investigated the relationship of these 2 phenotypes and frequency of regulatory T cells (Tregs) in controlled and uncontrolled chronic HIV-1 infection...
  7. pmc Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus Gag antigens and conserved Gag epitopes
    Liguo Niu
    Department of Microbiology and Immunology, Miller School of Medicine, University of Miami, 1580 NW 10th Ave, Miami, FL, USA
    Vaccine 29:2110-9. 2011
    ..In addition, little is known regarding whether specific HIV-1 proteome components, such as highly conserved regions of the HIV-1, could enhance clinical responses following DC therapy...
  8. ncbi request reprint Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir
    Niamh Higgins
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
    Am J Addict 16:488-94. 2007
    ..These data indicate that chronic HIV treatment may be assisted with plasma concentration monitoring to identify those patients who may require dosage modification and/or regimen adjustment in order to optimize antiretroviral effects...
  9. ncbi request reprint Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application
    Kim Keil
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, New York 14260, USA
    Ther Drug Monit 29:103-9. 2007
    ..During 2 years, more than 100 batches of analyses have been performed and have proved the method is rugged, specific, and accurate. This assay method is currently used in the authors' clinical research program in TDM...
  10. ncbi request reprint Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV
    Qing Ma
    University at Buffalo, Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, NY, USA
    Pharmacogenomics 8:227-35. 2007
    ..We examined MDR1 single nucleotide polymorphisms in a cohort of patients in whom therapeutic drug monitoring is ongoing through a research protocol...
  11. ncbi request reprint Buprenorphine assay and plasma concentration monitoring in HIV-infected substance users
    Robin DiFrancesco
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY, USA
    J Pharm Biomed Anal 44:188-95. 2007
    ..Use of this combined BUP and ARV plasma concentration monitoring approach for a representative patient receiving BUP, atazanavir and efavirenz demonstrated its clinical application...
  12. ncbi request reprint Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)
    Pablo Tebas
    Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA 19104, USA
    J Acquir Immune Defic Syndr 45:193-200. 2007
    ..Subcutaneous limb fat loss continues to be one the most troubling side effects of long-term antiretroviral regimens. Nucleoside analogues and protease inhibitors (PIs) have been linked to the development of this complication...
  13. ncbi request reprint Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoring
    Judianne Slish
    Pharmacotherapy Research Center, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Amherst, New York 14260, USA
    Ther Drug Monit 29:560-5. 2007
    ..Further work is needed to assess the optimal dosing regimen when using LPV in HIV-infected substance users...
  14. doi request reprint Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel
    Scott M Hammer
    Division of Infectious Diseases, Columbia University College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032, USA
    JAMA 300:555-70. 2008
    ....
  15. ncbi request reprint Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy
    Jeff D Moore
    University of Alabama at Birmingham, Division of Clinical Pharmacology, Birmingham, AL, USA
    Antivir Ther 12:981-6. 2007
    ..Little is known about how commonly used dual-NRTI regimens affect the intracellular levels of NRTI-TPs, the active form of these drugs. This study investigates the effect of dual-NRTI therapy in intracellular NRTI-TP levels...
  16. doi request reprint Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV
    Ann C Collier
    University of Washington School of Medicine and Harborview Medical Center, Seattle, Washington 98104, USA
    HIV Clin Trials 9:91-102. 2008
    ....
  17. ncbi request reprint Interferon-alpha2b with protease inhibitor-based antiretroviral therapy in patients with AIDS-associated Kaposi sarcoma: an AIDS malignancy consortium phase I trial
    Susan E Krown
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Acquir Immune Defic Syndr 41:149-53. 2006
    ..This study establishes a safe dose of IFN that can be used with HAART and, potentially, with other inhibitors of KS in future clinical trials...
  18. ncbi request reprint A randomized study of serial telephone call support to increase adherence and thereby improve virologic outcome in persons initiating antiretroviral therapy
    Ann C Collier
    University of Washington School of Medicine and Harborview Medical Center, Seattle, WA 98104, USA
    J Infect Dis 192:1398-406. 2005
    ..Adherence to antiretroviral therapy is difficult, and methods to increase it are needed...
  19. ncbi request reprint Mutations in HIV-1 reverse transcriptase during therapy with abacavir, lamivudine and zidovudine in HIV-1-infected adults with no prior antiretroviral therapy
    Mounir Ait-Khaled
    GlaxoSmithKline Research and Development, Stevenage, UK
    Antivir Ther 7:43-51. 2002
    ..To evaluate HIV-1 reverse transcriptase (RT) drug resistance in patients receiving abacavir, lamivudine and zidovudine therapy...
  20. pmc Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter
    Lisa M Demeter
    University of Rochester School of Medicine and Dentistry, Rochester, New York 14642, USA
    J Clin Microbiol 40:2089-94. 2002
    ..The delay in the time required for HIV cultures to turn positive should be considered when attempting to obtain an HIV isolate from patients with suppression of plasma viral load...
  21. ncbi request reprint Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Hopital Bichat Claude Bernard, Department of Infectious Diseases, 46 rue Henri Huchard, Paris, Cedex 18 France 75877
    JAMA 288:222-35. 2002
    ..These updated recommendations are intended to guide practicing physicians actively involved in human immunodeficiency virus (HIV)- and acquired immunodeficiency syndrome (AIDS)-related care...
  22. ncbi request reprint Open-label study of a twice-daily indinavir 800-mg/ritonavir 100-mg regimen in protease inhibitor-naive HIV-infected adults
    Benjamin Young
    Rose Medical Center, Denver, CO, USA
    J Acquir Immune Defic Syndr 31:478-82. 2002
    ..In this study, twice-daily indinavir 800 mg/ritonavir 100 mg with two nucleoside reverse transcriptase inhibitors provided potent viral suppression and immunologic reconstitution in many PI-naive patients...
  23. pmc Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects
    Robert Dicenzo
    University at Buffalo, Buffalo, New York, USA
    Antimicrob Agents Chemother 47:1929-35. 2003
    ..Abacavir did not influence the pharmacokinetics or exposure parameters of either indinavir or efavirenz. The levels of efavirenz exposure were similar in subjects receiving efavirenz q12h or q24h...
  24. ncbi request reprint Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infection
    Martin S Hirsch
    Massachusetts General Hospital, Harvard Medical School, Boston, USA
    Clin Infect Dis 37:1119-24. 2003
    ..Hyperbilirubinemia (experienced by 31% of subjects), nausea (17%), abdominal pain (14%), and nephrolithiasis (13%) were the most common drug-related adverse events during the extension...
  25. ncbi request reprint Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection
    Gregory K Robbins
    Harvard Medical School, Boston, USA
    N Engl J Med 349:2293-303. 2003
    ..The optimal sequencing of antiretroviral regimens for the treatment of infection with human immunodeficiency virus type 1 (HIV-1) is unknown. We compared several different antiretroviral treatment strategies...
  26. ncbi request reprint Association of T cell proliferative responses and phenotype with virus control in chronic progressive HIV-1 disease
    Uma Malhotra
    Program in Infectious Diseases, Clinical Research Division, Fred Hutchinson Cancer Research Center, and Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98109, USA
    J Infect Dis 189:515-9. 2004
    ..These findings indicate that Fas coexpression on T cells, in addition to plasma HIV-1 RNA levels and CD4+ T cell counts, may predict virologic outcome...
  27. ncbi request reprint A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir
    Scott M Hammer
    Columbia University, New York, NY, USA
    Antivir Ther 8:507-18. 2003
  28. pmc Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects
    Robert Dicenzo
    University at Buffalo, Buffalo, New York 14260, USA
    Antimicrob Agents Chemother 48:918-23. 2004
    ..5 to 5,540 ng/ml). Due to the unacceptable number of undetectable indinavir trough concentrations, 1200 mg of indinavir appears to be the preferred dose in a twice-daily regimen that includes nelfinavir...
  29. ncbi request reprint Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA Panel
    Patrick G Yeni
    Department of Infectious Diseases, Hopital Bichat Claude Bernard, X Bichat Medical School, Paris, France
    JAMA 292:251-65. 2004
    ..Substantial changes in the field of human immunodeficiency virus (HIV) treatment have occurred in the last 2 years, prompting revision of the guidelines for antiretroviral management of adults with established HIV infection...
  30. ncbi request reprint HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388
    Lisa M Demeter
    Infectious Diseases Unit, University of Rochester, Rochester, New York 14642, USA
    Clin Infect Dis 39:552-8. 2004
    ..Thus, although dual resistance to efavirenz and lamivudine occurred at VF in the efavirenz-indinavir arm, this risk was relatively low when evaluated in the context of the potency and tolerability of this regimen...
  31. pmc Pharmacokinetics of nelfinavir and efavirenz in antiretroviral-naive, human immunodeficiency virus-infected subjects when administered alone or in combination with nucleoside analog reverse transcriptase inhibitors
    Patrick F Smith
    Adult ACTG Pharmacology Support Laboratory, Laboratory for Antiviral Research, Department of Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, Buffalo, NY 12460, USA
    Antimicrob Agents Chemother 49:3558-61. 2005
    ..There were no significant differences in efavirenz pharmacokinetics...
  32. ncbi request reprint Response to lamivudine-zidovudine plus abacavir twice daily in antiretroviral-naive, incarcerated patients with HIV infection taking directly observed treatment
    Larry R Kirkland
    Burnside Clinic, Columbia, SC, USA
    Clin Infect Dis 34:511-8. 2002
    ..The overall adherence to prescribed doses was 94% for patients who remained enrolled in the study. COM-abacavir given twice daily was generally well tolerated, and adverse events prompted only 4 patients to withdraw from the study...

Research Grants2

  1. Miami HIV/AIDS Clinical Therapeutic and Vaccine Trial Unit
    Margaret Fischl; Fiscal Year: 2007
    ..The proposed clinical trials and investigations will advance our understanding of the treatment and pathogenesis of HIV/AIDS, and lead to improved care and prevention of HIV. ADMINISTRATIVE COMPONENT: ..